What is the clinical evidence from this study?

Study design: RCT. Population: Non-insulin dependent diabetes mellitus (NIDDM) with coronary stent implantation (n=52). Intervention: Troglitazone vs. Control. Primary outcome: Intimal index at six-month follow-up (p=<0.0001).

What question did this study set out to answer?

To evaluate whether troglitazone therapy suppresses neointimal tissue proliferation and prevents in-stent restenosis after coronary stent implantation in patients with non–insulin dependent diabetes mellitus.

May 19, 2026Journal of the American College of Cardiology

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus

Q: What are the key findings of this study?

Troglitazone significantly reduced the intimal index compared to control (27.1% vs 49.0%, P<0.0001) at six months after coronary stent implantation in patients with NIDDM.

Q: What question did this study set out to answer?

To evaluate whether troglitazone therapy suppresses neointimal tissue proliferation and prevents in-stent restenosis after coronary stent implantation in patients with non–insulin dependent diabetes mellitus.

View Full Paper

Ask AI

Bookmark

Key result

Troglitazone cuts post-stent intimal index ~45% vs control at six months in NIDDM.

P<0.0001
n=52

Why the study?

Does troglitazone reduce neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus?

Key Points

To evaluate whether troglitazone therapy suppresses neointimal tissue proliferation and prevents in-stent restenosis after coronary stent implantation in patients with non–insulin dependent diabetes mellitus.
A total of 52 patients with non–insulin dependent diabetes mellitus and 62 stented lesions were randomized to receive troglitazone (400 mg/day; n=25 patients, 29 stents) or standard control care (n=27 patients, 33 stents) for six months.
Patients underwent oral glucose tolerance tests and serial intravascular ultrasound (postintervention and at six-month follow-up) to measure stent area, lumen area, and intimal area across 1-mm cross sections.
Troglitazone produced significantly greater six-month reductions in sum of plasma glucose (-21.4 ± 8.8% vs. -4.5 ± 7.4%, p < 0.0001) and sum of insulin levels (-31.4 ± 17.9% vs. -1.9 ± 15.1%, p < 0.0001) compared with control.
At six-month intravascular ultrasound follow-up, the troglitazone group exhibited significantly larger lumen area (5.3 ± 1.7 mm² vs. 3.7 ± 1.7 mm², p = 0.0002), smaller intimal area (2.0 ± 0.9 mm² vs. 3.5 ± 1.8 mm², p < 0.0001), and a lower intimal index (27.1 ± 11.5% vs. 49.0 ± 14.4%, p < 0.0001) than controls, despite similar stent areas.

Study Design

Type

RCT (n=52)

Randomization

randomized

Structured PICO

Does troglitazone reduce neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus?

Population

52 patients with non-insulin dependent diabetes mellitus undergoing coronary stent implantation, followed for six months.

Intervention

Troglitazone 400 mg for a six-month treatment period.

Comparator

Control group (no specific placebo or matching strategy described).

Outcome

Neointimal tissue proliferation assessed by intimal area (IA) and intimal index at six-month follow-up using serial intravascular ultrasound.surrogate

Main Result

Absolute Event Rate: 27.1% vs 49%

p-value: p=<0.0001

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Troglitazone significantly reduces neointimal tissue proliferation and increases lumen area at 6 months after coronary stent implantation in patients with non-insulin dependent diabetes mellitus.

Cite This Study

Takagi et al. (2000) conducted an RCT in Non-insulin dependent diabetes mellitus (NIDDM) with coronary stent implantation (n=52). Troglitazone vs. Control was evaluated on Intimal index at six-month follow-up (p=<0.0001). Troglitazone significantly reduced the intimal index compared to control (27.1% vs 49.0%, P<0.0001) at six months after coronary stent implantation in patients with NIDDM.

synapsesocial.com/papers/6a0c2b07aff5732a0d7306f6 https://doi.org/10.1016/s0735-1097(00)00895-0

View Full Paper

Ask AI

Bookmark

Implication

Troglitazone significantly reduces neointimal tissue proliferation and increases lumen area at 6 months after coronary stent implantation in patients with non-insulin dependent diabetes mellitus.

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider